Morgan Stanley’s Citius Oncology CTOR Stock Holding History

Morgan Stanley’s Portfolio CTOR Stock Details CTOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5	Closed	-$10	–	8524
2025 Q3	$10	Buy	+5	New	+$11	﹤0.01%	8100

Other funds holding CTOR

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley's CTOR Position: Q4 2025 in Review

Morgan Stanley sold out of Citius Oncology (CTOR) in Q4 2025, closing a stake of 5 shares — an estimated $10 sold.

Morgan Stanley first reported a position in CTOR in Q3 2025 and held it in 1 quarter. The position peaked at $10 in Q3 2025. 18 funds tracked by Wall St. Rank hold CTOR as of Q4 2025.

Morgan Stanley reported no remaining Citius Oncology position as of Q4 2025 after selling out during the quarter.
Morgan Stanley sold 5 Citius Oncology shares in Q4 2025, an estimated $10.
Morgan Stanley first reported a position in Citius Oncology in Q3 2025 and held it in 1 quarter.
Morgan Stanley's Citius Oncology position peaked at $10 in Q3 2025.
18 funds tracked by Wall St. Rank held Citius Oncology as of Q4 2025.

Based on Morgan Stanley's 13F filing for Q4 2025, filed 13 Feb 2026.